Our People

Meet Our Executives

Our President and CEO

Dr. Sasi Suda


Management & Medical Team

Our President and CEO

Dr. Sasi Suda – MD, PhD (USyd)

Dr Sasi Suda is the Chief Executive Officer at GreenLight Clinical.

Dr. Suda is qualified as a medical practitioner in Australia and has extensive experience in the pharmaceutical industry and clinical research as both a researcher and clinical trial professional.

This combined clinical experience and research training has been applied across multiple positions in the pharmaceutical, biotechnology and medical industries in Australia, and Dr Suda has held key executive and clinical management roles at Alcon Laboratories, Novo Nordisk Pharmaceuticals and Avexa Australia.

Over the past 15 years, Dr Suda has served variously as a clinical research specialist in diverse areas including regulatory affairs, protocol development and compliance, site management, clinical operations, and drug safety and pharmacovigilance.

Our Executives

Associate Professor Andrew Chang – MBBS(Hons), PhD, FRANZCO, FRACS

Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. He holds an academic appointment of Clinical Associate Professor at the University of Sydney. He is Consultant Vitreoretinal Surgeon and the Head of the Retinal Unit at the Sydney Eye Hospital. He is the Medical Director of Sydney Retina Clinic.

He graduated from University of Sydney Medical School, underwent ophthalmology training at the Sydney Eye Hospital and fellowship training at Royal Victorian Eye and Ear Hospital and in the United States. He was awarded a PhD for research into retinal and choroidal angiography performed in the Universities of California and Sydney.

His commitment to international ophthalmology includes Secretary General of the Asia-Pacific Vitreoretinal Society (APVRS). He is a clinician advisor to the Department of Health Australia. He is a Director of the RANZCO Board and the Sydney Eye Hospital Foundation Board. Professional awards include the Achievement Award and Distinguished Service Award of the Asia Pacific Academy of Ophthalmology (APAO) and the RANZCO Excellence in Teaching Award.

Associate Professor Chang is enthusiastically involved in basic science and clinical trials research receiving research grant funding in Australia and USA. His research is extensively published in peer-reviewed scientific literature. He serves on the editorial boards of scientific peer-reviewed journals including Clinical and Experimental Ophthalmology.

In wider healthcare activities, Associate Professor Chang is engaged in the complexities of modern hospital healthcare delivery. He supports new medical drug and devices by engaging in clinical trials development. He is driving strategies aimed at better patient engagement with healthcare professionals using the latest in cloud, IoT and Artificial Intelligence.

Our Management and Medical Team

Chief Medical Officer – Dr Arthur Fischer

Dr Arthur Fischer graduated from the University of NSW and trained in Anatomical Pathology at the Prince of Wales and St George Hospitals in Sydney.

Dr. Fischer has over 30 years of experience in clinical pathology and private practice across Australia with a strong academic focus on dermatopathology in clinical settings.  He has served as an Examiner in Dermatopathology for the College of Dermatology in Australasia and was awarded Membership of the College for his services to Dermatology. 

He has also been active in the Royal College of Pathologists of Australasia, and is an expert reviewer for the Journal of the Australasian College of Dermatology.

Dr. Fischer’s experience in clinical research and long track record in commercial pathology across the Asia-Pacific region ensure that patient safety is at the core of all services we provide here at GreenLight Clinical.

Senior Medical Advisor – Dr Meidong Zhu MBBS, MMeD PhD (USyd)

Dr Meidong Zhu obtained her MBBS, and MMed of Ophthalmology from Nanjing Medical University in 1982 and 1988, respectively. She was later awarded PhD in Ophthalmology in 1998 by University of Sydney, Australia. Currently Dr Zhu works as a Senior Hospital Scientist in Lions New South Wales Eye Bank, New South Wales Tissue Bank and Australian Ocular Biobank in Sydney, Australia. As an Honorary Senior Lecturer in University of Sydney, she supervises students in Master of Medicine, Master of Philosophy and Doctor of Philosophy studies in School of Medicine of the University. Other positions Dr Zhu holds include Honorary Professor of the First Clinical Medical College, Nanjing Medical University, Medical Advisor in Jiangsu Province Eye Bank,Specialty Consultant in Aier Eye Hospital Group Co. Ltd and Board Member of the Overseas Chinese Association for Visual and Eye Research, Senior Medical Adviser in Greenlight Clinical Ptd Ltd, Australia.

Dr Meidong Zhu has been engaged in clinical ophthalmology, ocular scientific research and teaching, in Australia, China and other countries since her graduation. Her special interests are in retinal and fundus disease, corneal transplantation and eye banking. She also has expertise in various types of ophthalmic clinical trials, in both academic and commercial environments.  She has led or participated in more than 50 clinical trials and completed more than 40 research projects at all levels. She published more than 60 articles in the SIC journals. Dr Zhu also participated writing and editing books including “Macular Degeneration”, “Practical Technology in Modern Eye Bank”, “Eye and Vision Research Developments: Eye Disease Associated with Sleep Disorders” and other monographs.

Since 1995 Dr Meidong Zhu has been committing to and leading to the construction of Chinese modern eye banks. She has been introducing new technology to the Chinese Eye Banks in many cities, and at the same time, conducting staff training in Chinese Eye Banks. She also set up the relationship with China to help Chinese ophthalmologists participating in training at the Department of Ophthalmology, University of Sydney and Sydney Eye Hospital. In addition, Dr Meidong Zhu is committed to conduct global standardized drug clinical trials and GCP training in clinical trials in China.